TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma

TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma

Long noncoding RNAs (lncRNAs) have been indicated as critical regulators in osteosarcoma (OS). However, the function of lncRNAs in doxorubicin (DXR)-resistant OS remain unclear. Here, present study investigated the functions of lncRNA LINC00922 on the DXR resistance in OS tumorigenesis. LncRNA expre...

Full description

Bibliographic Details
Main Authors:	Zenghui Gu, Yuanxi Zhou, Chenye Cao, Xinqiang Wang, Liangbang Wu, Zhaoming Ye
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Doxorubicin-resistance LINC00922 Osteosarcoma TFAP2C
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332220305564

Similar Items

The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
by: Liping Wang, et al.
Published: (2021-06-01)

Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma
by: Lulin Wang, et al.
Published: (2020-07-01)

Distinct Activities of Tfap2A and Tfap2B in the Specification of GABAergic Interneurons in the Developing Cerebellum
by: Norliyana Zainolabidin, et al.
Published: (2017-08-01)

Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer
by: Damian Kołat, et al.
Published: (2021-02-01)

Corrigendum: Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer
by: Damian Kołat, et al.
Published: (2021-08-01)

Exosome‐transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma
by: Qiming Li, et al.
Published: (2020-09-01)

Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma
by: Martina Godel, et al.
Published: (2020-06-01)

The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma <it>in vitro</it>
by: Marley Kevin, et al.
Published: (2013-01-01)

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
by: Lisa M. Kopp, et al.
Published: (2019-10-01)

LINC01116 Promotes Doxorubicin Resistance in Osteosarcoma by Epigenetically Silencing miR-424-5p and Inducing Epithelial-Mesenchymal Transition
by: Ran Li, et al.
Published: (2021-03-01)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
by: Hye Jeong Park, et al.
Published: (2018-05-01)

LINC01535 Promotes the Development of Osteosarcoma Through Modulating miR-214-3p/KCNC4 Axis
by: Yao X, et al.
Published: (2020-07-01)

A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines
by: Fateme Haghiralsadat, et al.
Published: (2017-05-01)

β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1
by: Zhang S, et al.
Published: (2021-06-01)

Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression
by: Jiayi Chen, et al.
Published: (2021-06-01)

Down-regulation of LINC00472 promotes osteosarcoma tumorigenesis by reducing FOXO1 expressions via miR-300
by: Jingwei Zhang, et al.
Published: (2020-03-01)

In Vitro Delivery and Controlled Release of Doxorubicin for Targeting Osteosarcoma Bone Cancer
by: Tengku Azmi Tengku Ibrahim, et al.
Published: (2013-08-01)

A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro
by: Wei H, et al.
Published: (2019-11-01)

TFAP2A in the neural crest gene regulatory network and disease
by: Hallberg, Andrea Rachel
Published: (2019)

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma
by: Renna Qiu, et al.
Published: (2020-01-01)

Development, Characterization and Cell Viability Inhibition of PVA Spheres Loaded with Doxorubicin and 4′-Amino-1-Naphthyl-Chalcone (D14) for Osteosarcoma
by: Viviane Seba, et al.
Published: (2021-08-01)

Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells
by: Alessia Salzillo, et al.
Published: (2021-08-01)

LINC01278 is Highly Expressed in Osteosarcoma and Participates in the Development of Tumors by Mediating the miR-134-5p/KRAS Axis
by: Zhang GF, et al.
Published: (2021-01-01)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
by: Bin Zhang, et al.
Published: (2020-02-01)

Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma
by: Zhongkai Zhang, et al.
Published: (2020-11-01)

SP1-Induced Upregulation of lncRNA LINC00514 Promotes Tumor Proliferation and Metastasis in Osteosarcoma by Regulating miR-708
by: Mi LD, et al.
Published: (2020-05-01)

LINC01140 regulates osteosarcoma proliferation and invasion by targeting the miR-139-5p/HOXA9 axis
by: Chen, R., et al.
Published: (2022)

Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma
by: Yang P, et al.
Published: (2020-08-01)

Long non-coding RNA LINC01419 mediates miR-519a-3p/PDRG1 axis to promote cell progression in osteosarcoma
by: Zhiqian Gu, et al.
Published: (2020-05-01)

LncRNA LINC00588 Suppresses the Progression of Osteosarcoma by Acting as a ceRNA for miRNA-1972
by: Fu-Chao Zhou, et al.
Published: (2020-03-01)

Pathologic characterization and chemoresponsiveness to adriamycin of moloney sarcoma virus-induced osteosarcoma in the rat /
by: Olson, Harry Marshall
Published: (1977)

Silencing of LINC00707 suppresses cell proliferation, migration, and invasion of osteosarcoma cells by modulating miR-338-3p/AHSA1 axis
by: Zhang Xiao-rong, et al.
Published: (2021-07-01)

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy
by: Yongshuang Li, et al.
Published: (2020-01-01)

Family based and case–control designs reveal an association of TFAP2A in nonsyndromic cleft lip only among Vietnamese population
by: Duc Minh Nguyen, et al.
Published: (2021-09-01)

The Sensitization of Melatonin in Osteosarcoma Cells by Suppression of Anti-Apoptotic Proteins
by: Seyed Mostafa Mir, et al.
Published: (2020-06-01)

The effect of p53 on function of TFAP2C in breast cancer: detailed analysis of regulation of MUC1 gene
by: Li, Yingyue
Published: (2012)

MicroRNA‐576‐5p enhances the invasion ability of trophoblast cells in preeclampsia by targeting TFAP2A
by: Xiaoning Wang, et al.
Published: (2020-01-01)

Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance
by: Dong-Yu Wang, et al.
Published: (2016-05-01)

Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression
by: Takashi Higuchi, et al.
Published: (2019-10-01)

Circ_0001721 enhances doxorubicin resistance and promotes tumorigenesis in osteosarcoma through miR-758/TCF4 axis
by: Huapeng Guan, et al.
Published: (2021-07-01)